A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

NCT01951157 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Docetaxel
DRUG: Gemcitabine
DRUG: Lurbinectedin (PM01183)

Sponsor

PharmaMar